Plasma p‐tau231, p‐tau181, <scp>PET</scp> Biomarkers, and Cognitive Change in Older Adults
Pierre‐François Meyer(Douglas Mental Health University Institute), Sylvia Villeneuve(Douglas Mental Health University Institute), Alexa Pichet Binette(Lund University), Kaj Blennow(Sahlgrenska University Hospital), Juan Lantero‐Rodriguez(University of Gothenburg), Josef Pannee(Sahlgrenska University Hospital), Judes Poirier(Douglas Mental Health University Institute), Cherie Strikwerda‐Brown(Douglas Mental Health University Institute), Theresa Köbe(Humboldt-Universität zu Berlin), Hazal Ozlen(Douglas Mental Health University Institute), Thomas K. Karikari(University of Pittsburgh), John C.S. Breitner(Alzheimer’s Disease Neuroimaging Initiative), Anne Labonté, Yara Yakoub(Douglas Mental Health University Institute), Suzanne L. Baker(University of California, Berkeley), Michael Schöll(Wallenberg Wood Science Center), Eugeen Vanmechelen(ADx NeuroSciences), Henrik Zetterberg(University of Wisconsin–Madison), Nicholas J. Ashton(King's College London), Julie Gonneaud(Douglas Mental Health University Institute), Joel Simrén(University of Gothenburg)
Cited by 99
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k